AstraZeneca released a statement Sunday night because there were several cases of thrombosis recently among those who were vaccinated with their vaccine. In many countries, vaccination with their vaccine has been suspended.
Data from the 17 million people vaccinated so far in the European Union and the United Kingdom show that AstraZeneca does not pose a greater risk of developing pulmonary embolism, deep vein thrombosis or thrombocytopenia of any age, gender, group or country group.
The company writes in a statement.
Among those already vaccinated with the vaccine in the European Union and the United Kingdom, 15 cases of thrombosis and 22 pulmonary embolisms were reported by 8 March. This number is much lower than would be expected from general frequency data in a population of this size, and is similar to the number observed with other recorded COVID-19 vaccines. The European Medicines Agency (EMA) will publish an updated monthly safety report next week. ”
Additionally, we would like to note that although there were few cases of thrombosis in the clinical trials, the number was lower in the vaccine group than in the control group. However, 60,000 volunteers in the studies had no bleeding-related complications
– Keep calling.
It was also noted that “there is still no confirmed case of the AstraZeneca vaccine, in terms of quality, either in Europe or in the rest of the world.”
